On September 22, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, reported significant advancements in its global intellectual property portfolio, highlighted by (i) the acceptance of an Australian patent application and (ii) the issuance of a Notice of Allowance from the Japan Patent Office (JPO) for key technologies underpinning its RNA-based therapeutic platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IP Australia issued a Notice of Acceptance for Patent Application No. 2019349817, titled "Compositions and Methods for Immune Checkpoint Inhibition". The application covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for the treatment of cancer.
The allowed claims encompass nanoparticles comprising an iron oxide core, a dextran polymer coating, and a recited covalently linked siRNA, along with pharmaceutical compositions and methods of use across a broad range of cancers, including colon, lung, breast, pancreatic, and ovarian cancers.
In Japan, the Japan Patent Office (JPO) issued a Notice of Allowance, and subsequently granted and issued Japanese Patent No. 7886877, for Patent Application No. 2023-540752, titled "Template Directed Immunomodulation for Cancer Therapy." The application is directed to novel RNA-based immunomodulatory compositions, including single-stranded 5′ triphosphate-modified RNA oligonucleotides designed to selectively activate innate immune pathways such as RIG-I within tumors and the tumor microenvironment.
The allowed Japanese claims are related to compositions targeting cancers expressing miR-21, as well as nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems to enhance tumor targeting and cellular uptake.
"These milestones reflect the continued expansion and strengthening of our intellectual property portfolio in strategically important global markets," said Philippe P. Calais, Ph.D., Chairman and CEO of TransCode Therapeutics. "This provides additional support to our delivery platform and our emerging immuno-oncology capabilities, reinforcing our ability to develop differentiated RNA therapeutics designed to address critical unmet needs in cancer."
"These patent developments highlight the breadth of innovation underlying our platform," said Zdravka Medarova, Ph.D., Co-founder and CSO. "By integrating precise RNA design with targeted delivery technologies, we are advancing a new class of therapeutics designed to silence oncogenic drivers and activate innate immune pathways directly within tumors. We believe this dual approach represents a powerful potential to improve outcomes for patients with difficult-to-treat cancers."
The Australian patent application is expected to proceed to grant with a projected expiry date of September 6, 2039.
Collectively, these developments further strengthen TransCode’s global IP estate which encompasses its RNA-based therapeutic candidates, including TTX-MC138, and underscore the Company’s commitment to advancing innovative approaches that combine gene silencing and immune activation to treat cancer.
(Press release, TransCode Therapeutics, SEP 22, 2026, View Source [SID1234671003])